Ekobot expects to sell 25 of its unique farming robots this year, sign a distribution agreement in the Danish market and get one pilot customer
Biosergen has received approval for the next step in its phase 1 study of its drug against deadly fungal infections, which has blockbuster potential. Not
Biosergen AB stands in front of near-term price triggers and has a solid capital base to continue the development of the pipeline. 1.5 million people
Lifecare is trading at NOK 2.5, the price of the recently completed private placement, and there is therefore no need for a public issue at
Lifecare has completed a private placement of NOK 45 million at a 26% discount to yesterday’s price, equivalent to NOK 2.5 and a theoretical price
With investment from agriculture-based Dutch venture fund Navus Venures, Ekobot has not only gained new capital – at the market rate – but also, and
Mdundo A/S has today published the Q1 report for 2022/2023, which has offered new cooperation agreements and growth in the number of active users in
Listed EKOBOT’s high-tech agricultural robot is well positioned to take a significant share of the fast-growing market for agricultural robots, and investing in the company
Evaxion Biotech has announced that the first patient has been enrolled in the company’s Phase 2b clinical trial of EVX-01 for the treatment of melanoma.
InterMail has announced that it has initiated a “strategic review” and engaged an advisor to assist them. It comes after the share price last week
Kapital Partner performs or has within the last 12 months performed corporate finance, market relations, investor relations, Certified Adviser or other advisory activities for the following listed companies: NORD.investments, Biosergen, InterMail, Pila Pharma, Hypefactors, Curasight, Evaxion, Re-Match, Audientes, Mdundo.com, Nexcom.
Del indlægget på sociale media eller på email.